

# Arash O Naghavi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2818269/publications.pdf>

Version: 2024-02-01

48  
papers

1,233  
citations

471509

17  
h-index

377865

34  
g-index

48  
all docs

48  
docs citations

48  
times ranked

2272  
citing authors

#	ARTICLE	IF	CITATIONS
1	Proinflammatory Role for let-7 MicroRNAs in Experimental Asthma. <i>Journal of Biological Chemistry</i> , 2010, 285, 30139-30149.	3.4	222
2	Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. <i>Journal of Neuro-Oncology</i> , 2017, 133, 331-338.	2.9	107
3	Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 631-638.	0.8	102
4	Mouse let-7 miRNA populations exhibit RNA editing that is constrained in the 5'-seed/ cleavage/anchor regions and stabilize predicted mmu-let-7a:mRNA duplexes. <i>Genome Research</i> , 2008, 18, 1571-1581.	5.5	87
5	Radiation Therapy is Associated with Improved Outcomes in Merkel Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 3572-3578.	1.5	77
6	Treatment delays, race, and outcomes in head and neck cancer. <i>Cancer Epidemiology</i> , 2016, 45, 18-25.	1.9	74
7	The role of dose escalation and proton therapy in perioperative or definitive treatment of chondrosarcoma and chordoma: An analysis of the National Cancer Data Base. <i>Cancer</i> , 2019, 125, 642-651.	4.1	62
8	Radiosensitivity of Lung Metastases by Primary Histology and Implications for Stereotactic Body Radiation Therapy Using the Genomically Adjusted Radiation Dose. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1121-1127.	1.1	59
9	Novel MicroRNA Candidates and miRNA-mRNA Pairs in Embryonic Stem (ES) Cells. <i>PLoS ONE</i> , 2008, 3, e2548.	2.5	48
10	Patient choice for high-volume center radiation impacts head and neck cancer outcome. <i>Cancer Medicine</i> , 2018, 7, 4964-4979.	2.8	34
11	Radiosensitivity of Colon and Rectal Lung Oligometastasis Treated With Stereotactic Ablative Radiotherapy. <i>Clinical Colorectal Cancer</i> , 2017, 16, e211-e220.	2.3	33
12	The relationship between HPV status and chemoradiotherapy in the locoregional control of penile cancer. <i>World Journal of Urology</i> , 2018, 36, 1431-1440.	2.2	31
13	Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 473-482.	4.9	25
14	Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer. <i>Cancer</i> , 2016, 122, 634-641.	4.1	24
15	Genomic identification of sarcoma radiosensitivity and the clinical implications for radiation dose personalization. <i>Translational Oncology</i> , 2021, 14, 101165.	3.7	24
16	Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients <math>\geq 70</math>years. <i>Journal of Geriatric Oncology</i> , 2017, 8, 50-55.	1.0	23
17	The radiosensitivity of brain metastases based upon primary histology utilizing a multigene index of tumor radiosensitivity. <i>Neuro-Oncology</i> , 2017, 19, 1145-1146.	1.2	20
18	Sarcoma as a Model for Adolescent and Young Adult Care. <i>Journal of Oncology Practice</i> , 2019, 15, 239-247.	2.5	19

#	ARTICLE	IF	CITATIONS
19	Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization. <i>World Journal of Gastroenterology</i> , 2016, 22, 10406.	3.3	18
20	Clinical implications of a prostate-specific antigen bounce after radiation therapy for prostate cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 598-604.	2.2	15
21	Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 140-149.	3.9	15
22	Analysis of Relapse Events After Definitive Chemoradiotherapy in Locally Advanced Non-Small-Cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2019, 20, e1-e7.	2.6	14
23	Clinical Outcomes of Metastatic Melanoma Treated With Checkpoint Inhibitors and Multisite Radiotherapy. <i>JAMA Dermatology</i> , 2017, 153, 1056.	4.1	13
24	Management of Oropharyngeal Cancer in the HPV Era. <i>Cancer Control</i> , 2016, 23, 197-207.	1.8	11
25	Implications of staged reconstruction and adjuvant brachytherapy in the treatment of recurrent soft tissue sarcoma. <i>Brachytherapy</i> , 2016, 15, 495-503.	0.5	10
26	The Future of Radiation Oncology in Soft Tissue Sarcoma. <i>Cancer Control</i> , 2018, 25, 107327481881550.	1.8	6
27	Staged reconstruction brachytherapy has lower overall cost in recurrent soft-tissue sarcoma. <i>Journal of Contemporary Brachytherapy</i> , 2017, 1, 20-29.	0.9	5
28	Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial. <i>Radiotherapy and Oncology</i> , 2018, 127, 239-245.	0.6	5
29	Outcomes and the Role of Primary Histology Following LINAC-based Stereotactic Radiation for Sarcoma Brain Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 356-361.	1.3	5
30	Using the revised Edmonton symptom assessment scale during neoadjuvant radiotherapy for retroperitoneal sarcoma. <i>Clinical and Translational Radiation Oncology</i> , 2020, 22, 22-28.	1.7	5
31	Quantitatively Excessive Normal Tissue Toxicity and Poor Target Coverage in Postoperative Lung Cancer Radiotherapy Meta-analysis. <i>Clinical Lung Cancer</i> , 2018, 19, e123-e130.	2.6	4
32	Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience. <i>Melanoma Management</i> , 2018, 5, MMT02.	0.5	4
33	Novel Genomic-Based Strategies to Personalize Lymph Node Radiation Therapy. <i>Seminars in Radiation Oncology</i> , 2019, 29, 111-125.	2.2	4
34	TMPRSS2-ERG fusion impacts anterior tumor location in men with prostate cancer. <i>Prostate</i> , 2021, 81, 109-117.	2.3	4
35	American Brachytherapy Society (ABS) consensus statement for soft-tissue sarcoma brachytherapy. <i>Brachytherapy</i> , 2021, 20, 1200-1218.	0.5	4
36	Definitive Radiation Treatment Patterns and Outcomes for Low and Intermediate Risk Prostate Cancer Patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 937-944.	1.3	4

#	ARTICLE	IF	CITATIONS
37	Priming radioimmunotherapy with external beam radiation in patients with relapsed low grade non-Hodgkin lymphoma. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 129-138.	2.5	3
38	Extracranial metastatic burden in extensive-stage small cell lung cancer: implications for prophylactic cranial irradiation. <i>Journal of Thoracic Disease</i> , 2018, 10, 4321-4327.	1.4	3
39	Viral hepatitis associated hepatocellular carcinoma outcomes with yttrium-90 radioembolization. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 546-552.	1.4	3
40	American Brachytherapy Society radiation oncology alternative payment model task force: Quality measures and metrics for brachytherapy. <i>Brachytherapy</i> , 2022, 21, 63-74.	0.5	3
41	Quality of Life after post-prostatectomy intensity modulated radiation therapy to the prostate bed with or without the use of gold fiducial markers for image guidance or higher total radiotherapy doses. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2017, 43, 628-637.	1.5	2
42	Chemotherapy improves distant control in localized high-grade soft tissue sarcoma of the extremity/trunk. <i>Clinical Sarcoma Research</i> , 2020, 10, 11.	2.3	1
43	Viral hepatitis associated hepatocellular carcinoma outcomes with Y-90 radioembolization.. <i>Journal of Clinical Oncology</i> , 2016, 34, 414-414.	1.6	1
44	The impact of body mass index on dosimetric quality in low-dose-rate prostate brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2016, 5, 386-390.	0.9	0
45	The Impact of BMI on Dosimetric Quality in Low Dose Rate Prostate Brachytherapy. <i>Brachytherapy</i> , 2016, 15, S192-S193.	0.5	0
46	(P041) Effect of HPV/P16 Status on Response to Postoperative Radiotherapy (RT) in Squamous Cell Carcinoma of the Penis (PECA). <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, E26.	0.8	0
47	PO43. <i>Brachytherapy</i> , 2021, 20, S76.	0.5	0
48	Urinary and bowel quality of life after image-guided, intensity modulated radiation therapy to the prostate bed.. <i>Journal of Clinical Oncology</i> , 2016, 34, 312-312.	1.6	0